Physician profile
Robert M Gullberg
NPI 1669402541
$803.08
in general payments reported to CMS, 2019-2025
11 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $88.57 · 2021: $60.09 · 2022: $66.45 · 2023: $310 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $422.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $241.68 | 2019-2023 | Eliquis |
| Insmed, INC. | $171.43 | 2019-2025 | Arikayce |
| Alexion Pharmaceuticals, INC. | $121.07 | 2023 | Ultomiris |
| Amarin Pharma, INC. | $88.57 | 2020 | |
| Exact Sciences Corporation | $50.36 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Melinta Therapeutics, LLC | $30.48 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $29.68 | 2019-2021 | |
| Gilead Sciences, INC. | $26.77 | 2025 | |
| Paratek Pharmaceuticals, INC. | $19.16 | 2025 | Nuzyra |
| Amgen INC. | $12.51 | 2021 | |
| Mayne Pharma Commercial LLC | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gullberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.